Santen Pharmaceutical Co., Ltd. (FRA:SZD)

Santen Pharmaceutical Statistics

Total Valuation

FRA:SZD has a market cap or net worth of EUR 2.82 billion. The enterprise value is 2.46 billion.

Market Cap	2.82B
Enterprise Value	2.46B

Important Dates

The next estimated earnings date is Friday, February 6, 2026.

Earnings Date	Feb 6, 2026
Ex-Dividend Date	Sep 29, 2025

Share Statistics

Current Share Class	321.61M
Shares Outstanding	n/a
Shares Change (YoY)	-5.30%
Shares Change (QoQ)	-3.45%
Owned by Insiders (%)	0.12%
Owned by Institutions (%)	65.72%
Float	315.02M

Valuation Ratios

The trailing PE ratio is 15.57.

PE Ratio	15.57
Forward PE	n/a
PS Ratio	1.68
PB Ratio	1.79
P/TBV Ratio	2.48
P/FCF Ratio	12.60
P/OCF Ratio	10.59
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.43, with an EV/FCF ratio of 11.00.

EV / Earnings	13.59
EV / Sales	1.52
EV / EBITDA	7.43
EV / EBIT	10.66
EV / FCF	11.00

Financial Position

The company has a current ratio of 2.65

Current Ratio	2.65
Quick Ratio	1.72
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	35.16

Financial Efficiency

Return on equity (ROE) is 11.04% and return on invested capital (ROIC) is 9.42%.

Return on Equity (ROE)	11.04%
Return on Assets (ROA)	6.63%
Return on Invested Capital (ROIC)	9.42%
Return on Capital Employed (ROCE)	13.42%
Revenue Per Employee	436,136
Profits Per Employee	47,004
Employee Count	3,849
Asset Turnover	0.73
Inventory Turnover	2.25

Taxes

In the past 12 months, FRA:SZD has paid 59.16 million in taxes.

Income Tax	59.16M
Effective Tax Rate	24.89%

Stock Price Statistics

The stock price has decreased by -16.02% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-16.02%
50-Day Moving Average	8.70
200-Day Moving Average	9.02
Relative Strength Index (RSI)	50.79
Average Volume (20 Days)	1

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:SZD had revenue of EUR 1.68 billion and earned 180.92 million in profits. Earnings per share was 0.53.

Revenue	1.68B
Gross Profit	952.17M
Operating Income	243.83M
Pretax Income	237.72M
Net Income	180.92M
EBITDA	348.03M
EBIT	243.83M
Earnings Per Share (EPS)	0.53

Balance Sheet

The company has 366.06 million in cash and n/a in debt, giving a net cash position of 366.06 million.

Cash & Cash Equivalents	366.06M
Total Debt	n/a
Net Cash	366.06M
Net Cash Per Share	n/a
Equity (Book Value)	1.58B
Book Value Per Share	4.87
Working Capital	700.15M

Cash Flow

In the last 12 months, operating cash flow was 266.04 million and capital expenditures -42.45 million, giving a free cash flow of 223.58 million.

Operating Cash Flow	266.04M
Capital Expenditures	-42.45M
Free Cash Flow	223.58M
FCF Per Share	n/a

Margins

Gross margin is 56.72%, with operating and profit margins of 14.52% and 10.78%.

Gross Margin	56.72%
Operating Margin	14.52%
Pretax Margin	14.16%
Profit Margin	10.78%
EBITDA Margin	20.73%
EBIT Margin	14.52%
FCF Margin	13.32%

Dividends & Yields

This stock pays an annual dividend of 0.23, which amounts to a dividend yield of 2.61%.

Dividend Per Share	0.23
Dividend Yield	2.61%
Dividend Growth (YoY)	7.88%
Years of Dividend Growth	n/a
Payout Ratio	39.53%
Buyback Yield	5.30%
Shareholder Yield	7.90%
Earnings Yield	6.42%
FCF Yield	7.94%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 27, 2015. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2015
Split Type	Forward
Split Ratio	5

Scores

FRA:SZD has an Altman Z-Score of 5.14 and a Piotroski F-Score of 6.

Altman Z-Score	5.14
Piotroski F-Score	6